Singleron Bio Secures Nearly RMB 100 Million in Pre-A Financing to Accelerate Development and Clinical Application of High-Throughput Single-Cell Sequencing Products

According to Artery New Medicine (WeChat: biobeat1), Singleron Biotechnologies Co., Ltd. (“Singleron”), a company focused on the clinical application of high-throughput single-cell sequencing, recently secured nearly RMB 100 million in Pre-A series financing. This round was led by Sherpa Capital, with participation from Huachuang Capital and existing investors Yuanhe Yuandian and FreeS Fund.

This funding round will accelerate Singleron’s efforts to bring its proprietary, innovative high-throughput single-cell sequencing technology into clinical applications. This includes the development and commercialization of new products such as automated instruments, the establishment of clinical testing laboratories, the construction of a single-cell clinical database, and the expansion of its marketing team and distribution channels. In May 2018, Singleron secured tens of millions of RMB in angel-round financing led by Yuanhe Yuandian, with participation from FreeS Fund. To date, Singleron’s total fundraising has exceeded RMB 100 million.

Singleron, established in January 2018, is dedicated to developing simple and reliable high-throughput single-cell omics technologies, positioning them as next-generation molecular diagnostic tools. This enables single-cell omics to serve the fields of precision medicine and health management with unprecedented accuracy, sensitivity, and resolution compared to traditional methods. Since its inception, the company has rapidly attracted a cohort of high-level innovative and entrepreneurial talents. Currently, Singleron maintains laboratory and office facilities in Nanjing and Suzhou, employing over 60 full-time staff members. Among them, six hold doctoral degrees and possess overseas work experience, and have been selected for talent introduction programs such as “Entrepreneurship in Jiangbei,” “Entrepreneurship in Nanjing,” and “Major Leading Talents in Suzhou Industrial Park.” The core team members bring years of experience in genetic testing, microfluidic system R&D, development of reagents for single-cell amplification and library preparation, bioinformatics analysis and database construction, instrument design and development, as well as clinical assay product development and commercialization. They boast mature and profound expertise in technological innovation and product development, along with a track record of successful commercial translation.

Currently, the single-cell analysis market has exceeded RMB 10 billion and is rapidly transitioning from basic research to clinical applications. As one of the first companies in China to independently develop single-cell multi-omics sequencing products, Singleron has filed patent applications for more than ten core technologies and obtained software copyrights. In January 2019, it launched China’s first high-throughput single-cell sequencing product—the Singleron GEXSCOPE™ High-Throughput Single-Cell RNA Sequencing Product. This offering provides a comprehensive solution that includes self-developed microfluidic chips, all supporting reagents, and bioinformatics analysis software. Furthermore, leveraging its independently developed and manufactured high-throughput single-cell sequencing platform, the company has established collaborative projects with dozens of renowned research institutions and hospitals both domestically and internationally, jointly advancing the clinical translation of single-cell omics.

Singleron upholds the innovative philosophy of “investigating things to acquire knowledge, and discerning the subtle to comprehend the fundamental,” dedicating itself to developing simple and reliable high-throughput single-cell omics technologies. By establishing these as next-generation molecular detection methods, Singleron enables single-cell omics to serve the fields of precision medicine and health management with high accuracy, high sensitivity, and high resolution.

Sherpa Capital is a professional healthcare investment fund established in 2018. Its core team members have collaborated for nearly a decade, boasting extensive investment experience and a strong track record in China’s healthcare industry.

Sherpa, meaning “people of the east” in Tibetan, is an ethnic group residing on both sides of the Himalayan Mountains, renowned as “guides to Mount Everest.” The Sherpa team is committed to being the climbers behind the climbers, empowering entrepreneurs to scale the pinnacle of their careers.

HuaChuang Capital is a top-tier early-stage investment firm in China, providing venture capital to startups during their initial phases. With a primary focus on the Chinese market and a presence in Silicon Valley, USA, HuaChuang Capital has specialized since its establishment in 2006 in early-stage investments in new finance, new real economy industries, and new consumption sectors. Leveraging its extensive resources and expertise, the firm assists its portfolio companies with strategic planning, business expansion, and team building. Currently, HuaChuang Capital manages RMB and USD funds totaling RMB 8 billion, with investments spanning from the angel round to Series C.

Yuanhe Origin, a member enterprise of Suzhou Yuanhe Holdings Co., Ltd., was established in 2013 as a market-oriented, specialized equity investment platform focused on early- to mid-stage ventures. It primarily targets investment opportunities in startups and growth-stage companies within the Healthcare and TMT sectors. With an investment style that emphasizes early-stage deals and a preference for technology-driven innovations, Yuanhe Origin boasts a professional investment team, extensive experience, and substantial resource accumulation in the healthcare sector. The firm is committed to providing diverse value-added services to its portfolio companies to achieve mutual success. Its invested companies include Ascentage Pharma, CStone Pharmaceuticals, Biocytogen, and WuXi Juno Therapeutics.

FreeS Fund was established in 2015, focusing on early-stage and growth-early investments, with a primary emphasis on consumer sectors and deep technology. The fund prioritizes long-term value, adopts a research-driven approach, is committed to discovering innovation and excellence, and supports entrepreneurs throughout their growth journey. In the technology sector, FreeS Fund bets on technological forces that drive industrial upgrading and the application of technology in vertical domains. Its portfolio includes innovative companies such as Unity, QingTao Energy, SoundAI Technology, ZhaoGuan Electronics, ZeroZero Robotics, IceKredit, XtalPi, and Calterah.